ES2707885T3 - Alquilpirimidinderivados para el tratamiento de infecciones víricas y otras enfermedades - Google Patents

Alquilpirimidinderivados para el tratamiento de infecciones víricas y otras enfermedades Download PDF

Info

Publication number: ES2707885T3
Authority: ES; Spain
Prior art keywords: compounds; treatment; viral infections; modulation; formula
Prior art date: 2012-08-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES13748289T

Other languages

English (en)

Spanish (es)

Inventor

Gowan David Mc

Tim Jonckers

Pierre Raboisson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Janssen Sciences Ireland ULC

Original Assignee

Janssen Sciences Ireland ULC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-08-10

Filing date

2013-08-09

Publication date

2019-04-05

2013-08-09 Application filed by Janssen Sciences Ireland ULC filed Critical Janssen Sciences Ireland ULC

2019-04-05 Application granted granted Critical

2019-04-05 Publication of ES2707885T3 publication Critical patent/ES2707885T3/es

Status Active legal-status Critical Current

2033-08-09 Anticipated expiration legal-status Critical

Links

208000036142 Viral infection Diseases 0.000 title claims abstract description 8
230000009385 viral infection Effects 0.000 title claims abstract description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 6
201000010099 disease Diseases 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims abstract description 33
102000002689 Toll-like receptor Human genes 0.000 claims abstract description 21
108020000411 Toll-like receptor Proteins 0.000 claims abstract description 21
150000003839 salts Chemical class 0.000 claims abstract description 11
125000003118 aryl group Chemical group 0.000 claims abstract description 10
101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims abstract description 7
102100033110 Toll-like receptor 8 Human genes 0.000 claims abstract description 7
125000000623 heterocyclic group Chemical group 0.000 claims abstract description 6
239000012453 solvate Substances 0.000 claims abstract description 6
125000002618 bicyclic heterocycle group Chemical group 0.000 claims abstract description 4
239000001257 hydrogen Substances 0.000 claims abstract description 4
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 4
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract description 3
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 3
GBUHVEFCTQINBK-UHFFFAOYSA-N 4-n-pentyl-5-(2-phenylethyl)pyrimidine-2,4-diamine Chemical compound CCCCCNC1=NC(N)=NC=C1CCC1=CC=CC=C1 GBUHVEFCTQINBK-UHFFFAOYSA-N 0.000 claims abstract description 3
210000004027 cell Anatomy 0.000 description 11
239000000203 mixture Substances 0.000 description 11
230000000694 effects Effects 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
239000002552 dosage form Substances 0.000 description 7
238000000034 method Methods 0.000 description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
239000003814 drug Substances 0.000 description 6
241000282412 Homo Species 0.000 description 5
229940079593 drug Drugs 0.000 description 5
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
239000007787 solid Substances 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000000654 additive Substances 0.000 description 3
238000003556 assay Methods 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
239000000411 inducer Substances 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000000843 powder Substances 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
239000002904 solvent Substances 0.000 description 3
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
241000711549 Hepacivirus C Species 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
108060001084 Luciferase Proteins 0.000 description 2
239000005089 Luciferase Substances 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
102100039390 Toll-like receptor 7 Human genes 0.000 description 2
150000001447 alkali salts Chemical class 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
238000010276 construction Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
-1 cyclic sulfones Chemical class 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
125000005842 heteroatom Chemical group 0.000 description 2
102000045715 human TLR7 Human genes 0.000 description 2
238000011534 incubation Methods 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
239000007788 liquid Substances 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
244000052769 pathogen Species 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
150000003230 pyrimidines Chemical class 0.000 description 2
230000004044 response Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
125000006413 ring segment Chemical group 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
241000894007 species Species 0.000 description 2
239000000758 substrate Substances 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
238000001890 transfection Methods 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
XQSJHQXYQAUDFC-UHFFFAOYSA-N 4,6-dichloropyrimidine-5-carbaldehyde Chemical compound ClC1=NC=NC(Cl)=C1C=O XQSJHQXYQAUDFC-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
JECCXUZEDSOYEP-UHFFFAOYSA-N C=Cc(c(Cl)nc(N)n1)c1Cl Chemical compound C=Cc(c(Cl)nc(N)n1)c1Cl JECCXUZEDSOYEP-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
OAPBIRKSAUEKKJ-UHFFFAOYSA-N Cc1c(C=O)c(Cl)nc(N)n1 Chemical compound Cc1c(C=O)c(Cl)nc(N)n1 OAPBIRKSAUEKKJ-UHFFFAOYSA-N 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 1
101000763537 Homo sapiens Toll-like receptor 10 Proteins 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 1
101100481581 Mus musculus Tlr13 gene Proteins 0.000 description 1
108010021466 Mutant Proteins Proteins 0.000 description 1
102000008300 Mutant Proteins Human genes 0.000 description 1
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
229940124613 TLR 7/8 agonist Drugs 0.000 description 1
241001441723 Takifugu Species 0.000 description 1
102100027010 Toll-like receptor 1 Human genes 0.000 description 1
102100027009 Toll-like receptor 10 Human genes 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
230000008484 agonism Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
239000002585 base Substances 0.000 description 1
230000006399 behavior Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
208000020403 chronic hepatitis C virus infection Diseases 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
230000000139 costimulatory effect Effects 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
150000004292 cyclic ethers Chemical class 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
230000015788 innate immune response Effects 0.000 description 1
210000005007 innate immune system Anatomy 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
210000004901 leucine-rich repeat Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229960000329 ribavirin Drugs 0.000 description 1
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
239000012646 vaccine adjuvant Substances 0.000 description 1
229940124931 vaccine adjuvant Drugs 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

ES13748289T 2012-08-10 2013-08-09 Alquilpirimidinderivados para el tratamiento de infecciones víricas y otras enfermedades Active ES2707885T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP12180167		2012-08-10
PCT/EP2013/066673 WO2014023813A1 (en)	2012-08-10	2013-08-09	Alkylpyrimidine derivatives for the treatment of viral infections and further diseases

Publications (1)

Publication Number	Publication Date
ES2707885T3 true ES2707885T3 (es)	2019-04-05

Family

ID=48985736

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES13748289T Active ES2707885T3 (es)	2012-08-10	2013-08-09	Alquilpirimidinderivados para el tratamiento de infecciones víricas y otras enfermedades

Country Status (22)

Country	Link
US (1)	US9284304B2 (2)
EP (1)	EP2882721B1 (2)
JP (1)	JP6302906B2 (2)
KR (2)	KR102280589B1 (2)
CN (2)	CN104781239B (2)
AU (1)	AU2013301450B2 (2)
BR (1)	BR112015002524B1 (2)
CA (1)	CA2879617C (2)
CL (1)	CL2015000295A1 (2)
DK (1)	DK2882721T3 (2)
EA (1)	EA029266B1 (2)
ES (1)	ES2707885T3 (2)
IL (1)	IL236700A (2)
IN (1)	IN2015MN00478A (2)
MX (1)	MX369417B (2)
MY (1)	MY183534A (2)
NZ (1)	NZ703731A (2)
PH (1)	PH12015500274B1 (2)
SG (1)	SG11201500814UA (2)
UA (1)	UA115558C2 (2)
WO (1)	WO2014023813A1 (2)
ZA (1)	ZA201500921B (2)

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE055286T2 (hu)	2011-04-08	2021-11-29	Janssen Sciences Ireland Unlimited Co	Pirimidinszármazékok vírusfertõzések kezelésére
RS57851B1 (sr)	2011-11-09	2018-12-31	Janssen Sciences Ireland Uc	Purinski derivati za tretman viralnih infekcija
CA2874800C (en)	2012-07-13	2021-04-06	Janssen R&D Ireland	Macrocyclic purines for the treatment of viral infections
LT2906563T (lt)	2012-10-10	2018-06-11	Janssen Sciences Ireland Uc	Pirolo[3,2-d]pirimidino dariniai virusinių infekcijų ir kitų ligų gydymui
EP2925729B1 (en)	2012-11-16	2017-10-18	Janssen Sciences Ireland UC	Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
WO2014128189A1 (en)	2013-02-21	2014-08-28	Janssen R&D Ireland	2-aminopyrimidine derivatives for the treatment of viral infections
AU2014242954B2 (en)	2013-03-29	2018-03-15	Janssen Sciences Ireland Uc	Macrocyclic deaza-purinones for the treatment of viral infections
SG11201509520QA (en)	2013-05-24	2015-12-30	Janssen Sciences Ireland Uc	Pyridone derivatives for the treatment of viral infections and further diseases
BR112015032546B1 (pt)	2013-06-27	2022-05-17	Janssen Sciences Ireland Uc	Derivados de pirrolo[3,2-d]pirimidina e composição farmacêutica que os compreende para o tratamento de infecções virais e outras doenças
KR102322425B1 (ko)	2013-07-30	2021-11-05	얀센 사이언시즈 아일랜드 언리미티드 컴퍼니	바이러스 감염의 치료를 위한 티에노[3,2-d]피리미딘 유도체
WO2016141092A1 (en)	2015-03-04	2016-09-09	Gilead Sciences, Inc.	Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
WO2017035230A1 (en)	2015-08-26	2017-03-02	Gilead Sciences, Inc.	Deuterated toll-like receptor modulators
HK1257270A1 (zh)	2015-09-15	2019-10-18	Gilead Sciences, Inc.	用於治疗hiv的toll样受体(tlr)调节剂
UA125819C2 (uk)	2015-12-15	2022-06-15	Гіліад Сайєнсіз, Інк.	ВИДІЛЕНЕ МОНОКЛОНАЛЬНЕ АНТИТІЛО, ЩО ЗВ'ЯЗУЄТЬСЯ З gp120 ВІРУСУ ІМУНОДЕФІЦИТУ ЛЮДИНИ
CN109414508A (zh)	2016-05-27	2019-03-01	吉利德科学公司	使用ns5a、ns5b或ns3抑制剂治疗乙型肝炎病毒感染的方法
BR102017010009A2 (pt)	2016-05-27	2017-12-12	Gilead Sciences, Inc.	Compounds for the treatment of hepatitis b virus infection
AU2017289418B2 (en)	2016-07-01	2021-06-03	Janssen Sciences Ireland Unlimited Company	Dihydropyranopyrimidines for the treatment of viral infections
DE102016212307B4 (de)	2016-07-06	2018-02-22	Thyssenkrupp Ag	Verfahren zur Herstellung einer Zahnstange für ein Kraftfahrzeug, sowie Zahnstange für ein Lenkgetriebe
DE102016212303A1 (de)	2016-07-06	2018-01-11	Thyssenkrupp Ag	Zahnstange und ein Verfahren zur Herstellung einer Zahnstange für ein Lenkgetriebe eines Kraftfahrzeugs
DE102016212308B4 (de)	2016-07-06	2018-02-22	Thyssenkrupp Ag	Verfahren zur Herstellung einer Zahnstange für ein Lenkgetriebe eines Kraftfahrzeugs, sowie Zahnstange
DE102016212304B4 (de)	2016-07-06	2018-02-22	Thyssenkrupp Ag	Verfahren zur Herstellung einer Zahnstange für ein Lenkgetriebe eines Kraftfahrzeugs, sowie Zahnstange
JOP20190024A1 (ar)	2016-08-26	2019-02-19	Gilead Sciences Inc	مركبات بيروليزين بها استبدال واستخداماتها
CN109923106B (zh)	2016-09-02	2022-09-13	吉利德科学公司	toll样受体调节剂化合物
EP3507288B1 (en)	2016-09-02	2020-08-26	Gilead Sciences, Inc.	4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
JP7274415B2 (ja)	2016-09-29	2023-05-16	ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー	ウイルス感染症および他の疾患を処置するためのピリミジンプロドラッグ
IL265921B2 (en)	2016-10-14	2024-05-01	Prec Biosciences Inc	Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
US10662161B2 (en)	2017-01-30	2020-05-26	Regents Of The University Of Minnesota	Pyrimidines and uses thereof
TWI820984B (zh)	2017-01-31	2023-11-01	美商基利科學股份有限公司	替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
UY37581A (es)	2017-02-02	2018-08-31	Gilead Sciences Inc	Compuestos para el tratamiento de la infección por virus de la hepatitis b
BR102018007822A2 (pt)	2017-04-20	2018-11-06	Gilead Sciences, Inc.	composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
TWI687415B (zh) *	2017-08-17	2020-03-11	美商基利科學股份有限公司	Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) *	2017-08-17	2019-10-23	Gilead Sciences Inc	Formas de sal de colina de un inhibidor de la cápside del vih
JP6934562B2 (ja)	2017-08-22	2021-09-15	ギリアードサイエンシーズ，インコーポレイテッド	治療用複素環式化合物
WO2019084060A1 (en)	2017-10-24	2019-05-02	Silverback Therapeutics, Inc.	CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
WO2019118884A1 (en)	2017-12-15	2019-06-20	Silverback Therapeutics, Inc.	Antibody construct-drug conjugate for the treatment of hepatitis
CN111511754B (zh)	2017-12-20	2023-09-12	捷克共和国有机化学与生物化学研究所	活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
US10966999B2 (en)	2017-12-20	2021-04-06	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
TWI707849B (zh)	2018-02-13	2020-10-21	美商基利科學股份有限公司	Pd‐1/pd‐l1抑制劑
US10836746B2 (en)	2018-02-15	2020-11-17	Gilead Sciences, Inc.	Therapeutic compounds
WO2019161280A1 (en)	2018-02-16	2019-08-22	Gilead Sciences, Inc.	Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
PL3759109T3 (pl)	2018-02-26	2024-03-04	Gilead Sciences, Inc.	Podstawione związki pirolizyny jako inhibitory replikacji hbv
TW202415645A (zh)	2018-03-01	2024-04-16	愛爾蘭商健生科學愛爾蘭無限公司	２，４－二胺基喹唑啉衍生物及其醫學用途
WO2019195181A1 (en)	2018-04-05	2019-10-10	Gilead Sciences, Inc.	Antibodies and fragments thereof that bind hepatitis b virus protein x
TW202005654A (zh)	2018-04-06	2020-02-01	捷克科學院有機化學與生物化學研究所	２，２，─環二核苷酸
TWI833744B (zh)	2018-04-06	2024-03-01	捷克科學院有機化學與生物化學研究所	3'3'-環二核苷酸
TWI818007B (zh)	2018-04-06	2023-10-11	捷克科學院有機化學與生物化學研究所	2'3'-環二核苷酸
TW201945388A (zh)	2018-04-12	2019-12-01	美商精密生物科學公司	對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
KR102591947B1 (ko)	2018-04-19	2023-10-25	길리애드 사이언시즈, 인코포레이티드	Pd-1/pd-l1 억제제
WO2019211799A1 (en)	2018-05-03	2019-11-07	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
HRP20250618T1 (hr)	2018-07-03	2025-07-18	Gilead Sciences, Inc.	Protutijela koja ciljaju na hiv gp120 i postupci za uporabu
AU2019297362B2 (en)	2018-07-06	2022-05-26	Gilead Sciences, Inc.	Therapeutic heterocyclic compounds
US11186579B2 (en)	2018-07-06	2021-11-30	Gilead Sciences, Inc.	Therapeutic heterocyclic compounds
EP3820572B1 (en)	2018-07-13	2023-08-16	Gilead Sciences, Inc.	Pd-1/pd-l1 inhibitors
CN120053445A (zh)	2018-07-16	2025-05-30	吉利德科学公司	用于治疗hiv的衣壳抑制剂
WO2020028097A1 (en)	2018-08-01	2020-02-06	Gilead Sciences, Inc.	Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
US20200113912A1 (en)	2018-09-12	2020-04-16	Silverback Therapeutics, Inc.	Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates
WO2020072656A1 (en)	2018-10-03	2020-04-09	Gilead Sciences, Inc.	Imidozopyrimidine derivatives
US11236085B2 (en)	2018-10-24	2022-02-01	Gilead Sciences, Inc.	PD-1/PD-L1 inhibitors
TW202136261A (zh)	2018-10-31	2021-10-01	美商基利科學股份有限公司	經取代之6-氮雜苯并咪唑化合物
TWI721623B (zh)	2018-10-31	2021-03-11	美商基利科學股份有限公司	經取代之6-氮雜苯并咪唑化合物
WO2020176510A1 (en)	2019-02-25	2020-09-03	Gilead Sciences, Inc.	Protein kinase c agonists
WO2020176505A1 (en)	2019-02-25	2020-09-03	Gilead Sciences, Inc.	Protein kinase c agonists
US11766447B2 (en)	2019-03-07	2023-09-26	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
EP3935066A1 (en)	2019-03-07	2022-01-12	Institute of Organic Chemistry and Biochemistry ASCR, V.V.I.	3'3'-cyclic dinucleotides and prodrugs thereof
KR102707808B1 (ko)	2019-03-07	2024-09-19	인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이.	2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
WO2020197991A1 (en)	2019-03-22	2020-10-01	Gilead Sciences, Inc.	Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
TW202212339A (zh)	2019-04-17	2022-04-01	美商基利科學股份有限公司	類鐸受體調節劑之固體形式
TW202210480A (zh)	2019-04-17	2022-03-16	美商基利科學股份有限公司	類鐸受體調節劑之固體形式
TW202231277A (zh)	2019-05-21	2022-08-16	美商基利科學股份有限公司	鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
US11453681B2 (en)	2019-05-23	2022-09-27	Gilead Sciences, Inc.	Substituted eneoxindoles and uses thereof
US20220305115A1 (en)	2019-06-18	2022-09-29	Janssen Sciences Ireland Unlimited Company	Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
MX2021015533A (es)	2019-06-19	2022-02-10	Silverback Therapeutics Inc	Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
CR20210687A (es)	2019-06-25	2022-03-03	Gilead Sciences Inc	PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
TWI879779B (zh)	2019-06-28	2025-04-11	美商基利科學股份有限公司	類鐸受體調節劑化合物的製備方法
CN114761041A (zh)	2019-07-16	2022-07-15	吉利德科学公司	Hiv疫苗及其制备和使用方法
WO2021011891A1 (en)	2019-07-18	2021-01-21	Gilead Sciences, Inc.	Long-acting formulations of tenofovir alafenamide
WO2021034804A1 (en)	2019-08-19	2021-02-25	Gilead Sciences, Inc.	Pharmaceutical formulations of tenofovir alafenamide
CN119770638A (zh)	2019-09-30	2025-04-08	吉利德科学公司	Hbv疫苗和治疗hbv的方法
CA3151322A1 (en)	2019-10-01	2021-04-08	Silverback Therapeutics, Inc.	Combination therapy with immune stimulatory conjugates
CN114555123B (zh)	2019-10-18	2024-04-02	四十七公司	用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
KR20220091576A (ko)	2019-10-31	2022-06-30	포티 세븐, 인코포레이티드	혈액암의 항-cd47 및 항-cd20 기반 치료
TWI778443B (zh)	2019-11-12	2022-09-21	美商基利科學股份有限公司	Mcl1抑制劑
TWI854067B (zh)	2019-11-26	2024-09-01	美商基利科學股份有限公司	預防hiv之蛋白殼抑制劑
US12410418B2 (en)	2019-12-06	2025-09-09	Precision Biosciences, Inc.	Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
LT4081305T (lt)	2019-12-24	2024-11-25	Carna Biosciences, Inc.	Diacilglicerolio kinazę moduliuojantys junginiai
KR20260017503A (ko)	2020-02-14	2026-02-05	길리애드 사이언시즈, 인코포레이티드	Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도
JP7735291B2 (ja)	2020-02-21	2025-09-08	エーアールエスファーマシューティカルズ、インコーポレイテッド	ネクチン－４抗体コンジュゲートおよびその使用
US11718637B2 (en)	2020-03-20	2023-08-08	Gilead Sciences, Inc.	Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same
JP7564888B2 (ja)	2020-05-01	2024-10-09	ギリアードサイエンシーズ，インコーポレイテッド	Ｃｄ７３阻害性２，４－ジオキソピリミジン化合物
EP4153181A1 (en)	2020-05-21	2023-03-29	Gilead Sciences, Inc.	Pharmaceutical compositions comprising bictegravir
PL4172157T3 (pl)	2020-06-25	2026-03-23	Gilead Sciences, Inc.	Inhibitory kapsydu w leczeniu hiv
JP2023532304A (ja)	2020-07-01	2023-07-27	エーアールエスファーマシューティカルズオペレーションズ，インク．	抗ａｓｇｒ１抗体コンジュゲートおよびその使用
PE20230779A1 (es)	2020-08-07	2023-05-09	Gilead Sciences Inc	Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico
TWI815194B (zh)	2020-10-22	2023-09-11	美商基利科學股份有限公司	介白素2-Fc融合蛋白及使用方法
CN116437958A (zh)	2020-11-11	2023-07-14	吉利德科学公司	鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法
JP7717832B2 (ja)	2021-04-10	2025-08-04	ジェンマブエー／エス	Ｆｏｌｒ１結合剤、そのコンジュゲートおよびこれを使用する方法
TW202302145A (zh)	2021-04-14	2023-01-16	美商基利科學股份有限公司	ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
WO2022226317A1 (en)	2021-04-23	2022-10-27	Profoundbio Us Co.	Anti-cd70 antibodies, conjugates thereof and methods of using the same
EP4337223A1 (en)	2021-05-13	2024-03-20	Gilead Sciences, Inc.	Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics
TW202313094A (zh)	2021-05-18	2023-04-01	美商基利科學股份有限公司	使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
WO2022271659A1 (en)	2021-06-23	2022-12-29	Gilead Sciences, Inc.	Diacylglyercol kinase modulating compounds
WO2022271677A1 (en)	2021-06-23	2022-12-29	Gilead Sciences, Inc.	Diacylglyercol kinase modulating compounds
CA3222277A1 (en)	2021-06-23	2022-12-29	Gilead Sciences, Inc.	Diacylglyercol kinase modulating compounds
KR20240005901A (ko)	2021-06-23	2024-01-12	길리애드 사이언시즈, 인코포레이티드	디아실글리세롤 키나제 조절 화합물
TW202320857A (zh)	2021-07-06	2023-06-01	美商普方生物製藥美國公司	連接子、藥物連接子及其結合物及其使用方法
US20230183216A1 (en)	2021-10-28	2023-06-15	Gilead Sciences, Inc.	Pyridizin-3(2h)-one derivatives
EP4422756A1 (en)	2021-10-29	2024-09-04	Gilead Sciences, Inc.	Cd73 compounds
JP7765637B2 (ja)	2021-12-03	2025-11-06	ギリアードサイエンシーズ，インコーポレイテッド	Ｈｉｖウイルス感染症のための治療化合物
DK4445900T3 (da)	2021-12-03	2025-08-18	Gilead Sciences Inc	Terapeutiske forbindelser til hiv-virusinfektion
WO2023102523A1 (en)	2021-12-03	2023-06-08	Gilead Sciences, Inc.	Therapeutic compounds for hiv virus infection
WO2023107954A1 (en)	2021-12-08	2023-06-15	Dragonfly Therapeutics, Inc.	Antibodies targeting 5t4 and uses thereof
US20230203202A1 (en)	2021-12-08	2023-06-29	Dragonfly Therapeutics, Inc.	Proteins binding nkg2d, cd16 and 5t4
EP4452415B1 (en)	2021-12-22	2026-02-25	Gilead Sciences, Inc.	Ikaros zinc finger family degraders and uses thereof
CN118488946A (zh)	2021-12-22	2024-08-13	吉利德科学公司	Ikaros锌指家族降解剂及其用途
TW202340168A (zh)	2022-01-28	2023-10-16	美商基利科學股份有限公司	Ｐａｒｐ７抑制劑
CA3253296A1 (en)	2022-03-17	2023-09-21	Gilead Sciences, Inc.	Zinc Finger Degradation Agents of the Ikaros Family and Their Uses
AU2023240346A1 (en)	2022-03-24	2024-09-19	Gilead Sciences, Inc.	Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh)	2022-04-05	2025-03-11	美商基利科學股份有限公司	用於治療結腸直腸癌之組合療法
TWI856796B (zh)	2022-04-06	2024-09-21	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2023205719A1 (en)	2022-04-21	2023-10-26	Gilead Sciences, Inc.	Kras g12d modulating compounds
US20240116928A1 (en)	2022-07-01	2024-04-11	Gilead Sciences, Inc.	Cd73 compounds
TWI867601B (zh)	2022-07-01	2024-12-21	美商基利科學股份有限公司	可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物
CN119677546A (zh)	2022-07-12	2025-03-21	吉利德科学公司	Hiv免疫原性多肽和疫苗及其用途
KR20250051732A (ko)	2022-08-26	2025-04-17	길리애드 사이언시즈, 인코포레이티드	광범위 중화 항체를 위한 투여 및 일정 요법
WO2024064668A1 (en)	2022-09-21	2024-03-28	Gilead Sciences, Inc.	FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
EP4598934A1 (en)	2022-10-04	2025-08-13	Gilead Sciences, Inc.	4'-thionucleoside analogues and their pharmaceutical use
EP4638436A1 (en)	2022-12-22	2025-10-29	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
CN120882725A (zh)	2023-04-11	2025-10-31	吉利德科学公司	Kras调节化合物
US20240390349A1 (en)	2023-04-19	2024-11-28	Gilead Sciences, Inc.	Dosing regimen of capsid inhibitor
WO2024220917A1 (en)	2023-04-21	2024-10-24	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
US20250042926A1 (en)	2023-05-31	2025-02-06	Gilead Sciences, Inc.	Therapeutic compounds for hiv
KR20260018877A (ko)	2023-05-31	2026-02-09	길리애드 사이언시즈, 인코포레이티드	Hiv 치료에 유용한 화합물의 고체 형태
US20250042922A1 (en)	2023-06-30	2025-02-06	Gilead Sciences, Inc.	Kras modulating compounds
US20250066328A1 (en)	2023-07-26	2025-02-27	Gilead Sciences, Inc.	Parp7 inhibitors
AU2024297978A1 (en)	2023-07-26	2026-02-05	Gilead Sciences, Inc.	Parp7 inhibitors
KR20260046169A (ko)	2023-07-28	2026-04-06	길리애드 사이언시즈, 인코포레이티드	Hiv의 치료 및 예방을 위한 레나카파비르 주간 투여 레지먼
WO2025042394A1 (en)	2023-08-23	2025-02-27	Gilead Sciences, Inc.	Dosing regimen of hiv capsid inhibitor
WO2025054347A1 (en)	2023-09-08	2025-03-13	Gilead Sciences, Inc.	Kras g12d modulating compounds
AU2024337913A1 (en)	2023-09-08	2026-03-26	Gilead Sciences, Inc.	Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
AU2024353316A1 (en)	2023-09-26	2026-03-26	Genmab A/S	Ptk7 binding agents, conjugates thereof and methods of using the same
WO2025080850A1 (en)	2023-10-11	2025-04-17	Gilead Sciences, Inc.	Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202515549A (zh)	2023-10-11	2025-04-16	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2025080863A1 (en)	2023-10-11	2025-04-17	Gilead Sciences, Inc.	Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250154172A1 (en)	2023-11-03	2025-05-15	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
US20250230163A1 (en)	2023-12-22	2025-07-17	Gilead Sciences, Inc.	Solid forms of hiv integrase inhibitors
WO2025137640A1 (en)	2023-12-22	2025-06-26	Gilead Sciences, Inc.	Azaspiro wrn inhibitors
WO2025149661A1 (en)	2024-01-10	2025-07-17	Genmab A/S	Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025181219A1 (en)	2024-02-29	2025-09-04	Genmab A/S	Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2025184609A1 (en)	2024-03-01	2025-09-04	Gilead Sciences, Inc.	Antiviral compounds
WO2025184452A1 (en)	2024-03-01	2025-09-04	Gilead Sciences, Inc.	Solid forms of hiv integrase inhibitors
US20250296932A1 (en)	2024-03-01	2025-09-25	Gilead Sciences, Inc.	Pharmaceutical compositions comprising hiv integrase inhibitors
WO2025240246A1 (en)	2024-05-13	2025-11-20	Gilead Sciences, Inc.	Combination therapies with ribavirin
WO2025240242A1 (en)	2024-05-13	2025-11-20	Gilead Sciences, Inc.	Combination therapies with ribavirin
US20250345389A1 (en)	2024-05-13	2025-11-13	Gilead Sciences, Inc.	Combination therapies
WO2025240244A1 (en)	2024-05-13	2025-11-20	Gilead Sciences, Inc.	Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
US20250376484A1 (en)	2024-05-21	2025-12-11	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
US20260007683A1 (en)	2024-06-14	2026-01-08	Gilead Sciences, Inc.	Pharmaceutical compositions comprising hiv integrase inhibitors
WO2026039365A1 (en)	2024-08-12	2026-02-19	Gilead Sciences, Inc.	Kras modulating compounds
WO2026076265A1 (en)	2024-10-03	2026-04-09	Gilead Sciences, Inc.	Combination therapy comprising bridged tricyclic carbamoylpyridone compounds and p-glycoprotein inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE283855T1 (de)	1996-07-03	2004-12-15	Sumitomo Pharma	Neue purinderivate
NZ504800A (en)	1997-11-28	2001-10-26	Sumitomo Pharma	6-Amino-9-benzyl-8-hydroxy-purine derivatives and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases thereof
US6110929A (en)	1998-07-28	2000-08-29	3M Innovative Properties Company	Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
ES2221414T3 (es) *	1998-08-27	2004-12-16	Sumitomo Pharmaceuticals Company, Limited	Derivados de pirimidina.
US6583148B1 (en) *	1999-04-08	2003-06-24	Krenitsky Pharmaceuticals, Inc.	Neurotrophic substituted pyrimidines
EP1888587A1 (en)	2005-05-04	2008-02-20	Pfizer Limited	2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c
CA2691444C (en)	2007-06-29	2016-06-14	Gilead Sciences, Inc.	Purine derivatives and their use as modulators of toll-like receptor 7
PE20091236A1 (es) *	2007-11-22	2009-09-16	Astrazeneca Ab	Derivados de pirimidina como immunomoduladores de tlr7
WO2009134624A1 (en)	2008-04-28	2009-11-05	Merck & Co., Inc.	Hcv ns3 protease inhibitors
WO2012066335A1 (en) *	2010-11-19	2012-05-24	Astrazeneca Ab	Phenol compounds als toll -like receptor 7 agonists

2013
- 2013-08-09 CN CN201380042284.4A patent/CN104781239B/zh not_active Expired - Fee Related
- 2013-08-09 KR KR1020217004007A patent/KR102280589B1/ko not_active Expired - Fee Related
- 2013-08-09 AU AU2013301450A patent/AU2013301450B2/en not_active Ceased
- 2013-08-09 CN CN201811093741.3A patent/CN109232439A/zh active Pending
- 2013-08-09 EP EP13748289.9A patent/EP2882721B1/en active Active
- 2013-08-09 MY MYPI2015000167A patent/MY183534A/en unknown
- 2013-08-09 BR BR112015002524-2A patent/BR112015002524B1/pt not_active IP Right Cessation
- 2013-08-09 DK DK13748289.9T patent/DK2882721T3/en active
- 2013-08-09 NZ NZ703731A patent/NZ703731A/en not_active IP Right Cessation
- 2013-08-09 JP JP2015525892A patent/JP6302906B2/ja not_active Expired - Fee Related
- 2013-08-09 KR KR1020157003081A patent/KR102216479B1/ko not_active Expired - Fee Related
- 2013-08-09 WO PCT/EP2013/066673 patent/WO2014023813A1/en not_active Ceased
- 2013-08-09 ES ES13748289T patent/ES2707885T3/es active Active
- 2013-08-09 CA CA2879617A patent/CA2879617C/en active Active
- 2013-08-09 EA EA201590343A patent/EA029266B1/ru unknown
- 2013-08-09 MX MX2015001829A patent/MX369417B/es active IP Right Grant
- 2013-08-09 SG SG11201500814UA patent/SG11201500814UA/en unknown
- 2013-08-09 US US14/420,066 patent/US9284304B2/en active Active
- 2013-08-09 IN IN478MUN2015 patent/IN2015MN00478A/en unknown
- 2013-08-09 UA UAA201500301A patent/UA115558C2/uk unknown
2015
- 2015-01-13 IL IL236700A patent/IL236700A/en active IP Right Grant
- 2015-02-06 CL CL2015000295A patent/CL2015000295A1/es unknown
- 2015-02-09 ZA ZA2015/00921A patent/ZA201500921B/en unknown
- 2015-02-09 PH PH12015500274A patent/PH12015500274B1/en unknown

Also Published As

Publication number	Publication date
PH12015500274A1 (en)	2015-04-27
AU2013301450A1 (en)	2015-02-05
CN104781239B (zh)	2019-03-01
EA029266B1 (ru)	2018-02-28
IL236700A0 (en)	2015-02-26
IL236700A (en)	2017-02-28
JP6302906B2 (ja)	2018-03-28
DK2882721T3 (en)	2019-03-18
MX2015001829A (es)	2015-09-23
SG11201500814UA (en)	2015-03-30
KR102280589B1 (ko)	2021-07-22
WO2014023813A1 (en)	2014-02-13
US9284304B2 (en)	2016-03-15
IN2015MN00478A (2)	2015-09-04
BR112015002524B1 (pt)	2021-11-03
EP2882721B1 (en)	2018-12-05
CL2015000295A1 (es)	2015-04-24
KR20210018974A (ko)	2021-02-18
AU2013301450B2 (en)	2018-01-18
JP2015524462A (ja)	2015-08-24
US20150239872A1 (en)	2015-08-27
CN104781239A (zh)	2015-07-15
PH12015500274B1 (en)	2020-02-19
MX369417B (es)	2019-11-07
NZ703731A (en)	2018-03-23
CN109232439A (zh)	2019-01-18
BR112015002524A2 (pt)	2017-07-04
EP2882721A1 (en)	2015-06-17
CA2879617C (en)	2021-05-04
KR20150040910A (ko)	2015-04-15
HK1207636A1 (en)	2016-02-05
CA2879617A1 (en)	2014-02-13
EA201590343A1 (ru)	2015-05-29
UA115558C2 (uk)	2017-11-27
ZA201500921B (en)	2021-10-27
MY183534A (en)	2021-02-25
KR102216479B1 (ko)	2021-02-17

Publication	Publication Date	Title
ES2707885T3 (es)	2019-04-05	Alquilpirimidinderivados para el tratamiento de infecciones víricas y otras enfermedades
ES2716811T3 (es)	2019-06-17	Derivados piperidinopirimidínicos para el tratamiento de infecciones víricas
ES2733361T3 (es)	2019-11-28	Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas
ES2701239T3 (es)	2019-02-21	Derivados de tieno[3,2-d]pirimidinas para el tratamiento de infecciones virales
ES2670513T3 (es)	2018-05-30	Derivados pirrolo[3,2-d]pirimidínicos para el tratamiento de infecciones víricas y otras enfermedades
ES2655843T3 (es)	2018-02-21	Derivados 2-aminoquinazolínicos sustituidos heterocíclicos para el tratamiento de infecciones víricas
IL228317A (en)	2017-07-31	Pyrimidine derivatives and pharmaceutical preparations containing a signal
AU2013326579A1 (en)	2015-04-09	1,2,4-triazine derivatives for the treatment of viral infections.
ES2657283T3 (es)	2018-03-02	Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
HK40003405A (en)	2020-04-09	Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
HK1207636B (zh)	2020-02-07	用於治疗病毒感染和另外的疾病的烷基嘧啶衍生物
NZ709769B2 (en)	2021-02-02	2-aminopyrimidine derivatives for the treatment of viral infections